Details for Patent: 10,517,868

Which drugs does patent 10,517,868 protect, and when does it expire?

Patent 10,517,868 protects RECORLEV and is included in one NDA.

This patent has twenty-four patent family members in twenty countries.

Summary for Patent: 10,517,868

Title:	Methods and compositions for treating diabetes, metabolic syndrome and other conditions
Abstract:	Pharmaceuticals compositions comprising the 2S, 4R, ketoconazole enantiomer or its pharmaceutically acceptable salts, hydrates, and solvates, that are substantially free of the 2R, 4S ketoconazole enantiomer are useful to reduce cortisol synthese and for the treatment of type 2 diabetes, hyperglycemia, obesity, insulin resistance, dyslipidemia, hyperlipidemia, hypertension, Metabolic Syndrome, and other diseases and conditions, including but not limited to Cushing's Syndrome, depression, and glaucoma.
Inventor(s):	Marin; Per (Vastra Frolunda, SE)
Assignee:	Strongbridge Dublin Limited (Dublin, IE)
Application Number:	16/152,202
Patent Claim Types: see list of patent claims	Use; Composition;

Drugs Protected by US Patent 10,517,868

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Strongbridge	RECORLEV	levoketoconazole	TABLET;ORAL	214133-001	Dec 30, 2021		RX	Yes	Yes						TREATMENT OF ENDOGENOUS HYPERCORTISOLEMIA IN PATIENTS WITH CUSHING’S SYNDROME FOR WHOM SURGERY IS NOT AN OPTION OR HAS NOT BEEN CURATIVE

International Family Members for US Patent 10,517,868

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Austria	E528005
Australia	2006204334
Canada	2594433